Key Highlights

  • Moleculin reported blinded interim data showing a 37% composite complete remission rate across 62 evaluable acute myeloid leukemia patients, with a 37% rate even in the hardest-to-treat subgroup who had already failed venetoclax-based therapy.
  • The company priced a roughly $9.3 million public offering the same day as the data release, adding more than 12 million shares plus warrants for up to 37 million more against a weighted average share count of just 4.1 million.
  • The raise is intended to fund completion of Part A of the pivotal trial rather than the full program, with first-quarter operating expenses of $7.9 million meaning the gross proceeds cover close to a single quarter of spending.

Moleculin Biotech, Inc. (NASDAQ:MBRX) did two things on the same July morning that small drug developers usually do months apart: it released a fresh interim look at the most important trial it has ever run, and priced a stock sale to help pay for the rest of it.

The Houston company is testing Annamycin, an experimental anthracycline chemotherapy, in relapsed or refractory acute myeloid leukaemia - AML that has come back after treatment or never responded to it. The trial, MIRACLE, is a pivotal adaptive Phase 2b/3 study.

That pairing is why the stock is being watched: the data has held up as the trial has grown, while the Balance Sheet behind it stayed thin.

What Happened

On 31 July 2026 Moleculin reported blinded interim results from 62 evaluable subjects in Part A of MIRACLE. Across the pooled group, 24% achieved a complete remission (CR) - no detectable leukaemia in the bone marrow with recovered blood counts - and 37% achieved a composite complete remission (CRc), a broader measure that also counts remissions without full blood-count recovery.

The detail that drew attention was the venetoclax-failed subgroup. Thirty of the 62 patients, or 48%, had already failed venetoclax-based therapy, the standard first-line option for many older or unfit AML patients. In that subgroup Moleculin reported 23% CR and 37% CRc, against a retrospective single-institution analysis it cited (Maiti et al., Haematologica 2021) showing roughly 13% salvage CRc after frontline venetoclax failure.

The company flagged the limits: the data is blinded and so includes control-arm patients, and the historical figure is not a head-to-head control. Chief Executive Walter Klemp said the blinded CRc had held in a narrow band while the population became measurably harder to treat, with no evidence of cardiotoxicity observed. Hours later Moleculin priced a roughly $9.3 million public offering, which closed on 3 August.

Why It Matters

Patients who Fail venetoclax-based therapy are the hardest gap in AML. Once that combination stops working, salvage Options are limited and survival is typically measured in a few months, which is the point of the comparator Moleculin cited.

Anthracyclines are among the most effective AML drugs, but their use is capped by cumulative heart damage and blunted by multidrug resistance. Annamycin is engineered to sidestep both. Half of the responders in Moleculin's earlier Phase 1b/2 study went on to a potentially curative bone marrow transplant, so the drug's role as a bridge to transplant matters beyond the response rate.

The Numbers

The first unblinded interim look, disclosed on 30 June 2026, covered the first 45 patients on an intent-to-treat basis. CR rates were 43% for the 190 mg/m2 Annamycin arm and 36% for the 230 mg/m2 arm, against 12% for the control arm receiving high-dose cytarabine alone. Composite CR was 50% and 57%, versus 29% for control.

No statistical significance was reached at that look, by design: the trial preserves power for a final analysis at about 282 subjects. The independent data monitoring committee unanimously recommended continuing without dropping either dose arm.

A pooled cardiac analysis presented at ASCO in May 2026 covered 90 patients across five completed trials, 78 with matched heart-function measurements. Cumulative doses ran from 210 to 2,970 mg/m2, and the mean change in left ventricular ejection fraction was minus 0.12% (p=0.84). Independent Cleveland Clinic cardiologists found no evidence of drug-induced cardiac damage.

The financial picture is tighter. Moleculin ended March 2026 with $10.3 million in cash. First-quarter R&D spending rose to $5.4 million from $3.4 million, driven mainly by expanding MIRACLE into Europe, while general and administrative costs held at $2.5 million. The net loss was $12.8 million, and management said cash would fund operations into the third quarter of 2026.

What It Means for the Company

The August raise buys time to finish Part A rather than to fund the whole programme. Moleculin sold 12,376,667 shares or pre-funded warrants at $0.75, each paired with a five-year Series I Warrant exercisable at $0.75 covering up to 37,130,001 additional shares. Roth Capital Partners was exclusive Placement agent on a 6.5% cash fee, with Maxim Group as financial adviser. Proceeds are earmarked for Annamycin's clinical development and working capital.

Completing Part A matters because it drives the dose selection carried into Part B, the pivotal efficacy stage. Independent Market research published in June found hematologist-oncologists gave Annamycin an average likelihood-to-prescribe score of 6 out of 7, citing deep remissions and reduced cardiotoxicity. That is stated intent, not prescribing behaviour, and no product is approved.

Risks Investors Should Watch

Dilution is the most immediate. Against a weighted average share count of about 4.1 million in the first quarter, the offering added more than 12 million shares plus warrants over roughly 37 million more, with an exercise price that can reset downward to a $0.21 floor.

Cash burn is next. First-quarter operating expenses of about $7.9 million across R&D and G&A mean the $9.3 million gross raise, before fees, covers close to a single quarter at that rate. The deal was done off a Form S-1 declared effective 31 July 2026 rather than a shelf takedown, with a 45-day standstill on new Equity issuance attached.

Listing status deserves attention. Moleculin completed a 1-for-25 reverse split effective 1 December 2025, and shares changed hands around $0.57 on 13 August 2026, against Nasdaq's $1.00 minimum bid price requirement for continued listing; no deficiency notice appears in the filings reviewed here. Clinically, the July figures are blinded, and interim response rates in small populations move.

What Comes Next

Moleculin expects the final Part A subject to be treated in September 2026, with comprehensive unblinded Part A results anticipated between December 2026 and February 2027. That readout, and the dose decision following it, is the defining event for the programme.

Nearer term, second-quarter results are expected on or about 19 August 2026 according to consensus Earnings calendars, and should show the 30 June cash balance and updated runway language.

Conclusion

Moleculin's interim data is genuinely encouraging for the hardest population in AML treatment, patients who have already failed venetoclax-based therapy typically have few options left, and a 37% composite remission rate compares favorably to the historical benchmark the company cited. But the data is blinded, meaning it includes control-arm patients, and the historical comparison isn't a randomized control, so the strength of the signal won't be clear until the final analysis. The financing timed alongside the data release tells its own story: the offering funds completion of Part A specifically, not the full pivotal program, and at current burn rates the company will likely need to return to the market again before Part B even begins.